HXBM (Helix Biomedix) Cyclically Adjusted PB Ratio: (As of Aug. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Helix Biomedix Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Helix Biomedix  (OTCPK:HXBM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Helix Biomedix Cyclically Adjusted PB Ratio Related Terms


Helix Biomedix Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Helix Biomedix's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix Biomedix Cyclically Adjusted PB Ratio Chart

Helix Biomedix Annual Data
Trend Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Helix Biomedix Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HXBM vs XBIO, CBLI, ADYX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Helix Biomedix's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helix Biomedix Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix Biomedix's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Helix Biomedix's Cyclically Adjusted PB Ratio falls into.



Helix Biomedix Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Helix Biomedix's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2012 is calculated as:

For example, Helix Biomedix's adjusted Book Value per Share data for the three months ended in Sep. 2012 was:

Adj_Book=Book Value per Share/CPI of Sep. 2012 (Change)*Current CPI (Sep. 2012)
=6.928/231.4070*231.4070
=6.928

Current CPI (Sep. 2012) = 231.4070.

Helix Biomedix Quarterly Data

Book Value per Share CPI Adj_Book
200212 21.023 180.900 26.893
200303 29.209 184.200 36.695
200306 32.884 183.700 41.424
200309 27.802 185.200 34.739
200312 34.116 184.300 42.836
200403 39.000 187.400 48.158
200406 46.372 189.700 56.567
200409 39.628 189.900 48.290
200412 31.151 190.300 37.880
200503 51.965 193.300 62.209
200506 58.651 194.500 69.780
200509 50.058 198.800 58.268
200512 40.907 196.800 48.100
200603 63.558 199.800 73.612
200606 52.558 202.900 59.942
200609 43.384 202.900 49.479
200612 32.535 201.800 37.308
200703 48.256 205.352 54.379
200706 39.244 208.352 43.587
200709 29.465 208.490 32.704
200712 19.430 210.036 21.407
200803 -9.686 213.528 -10.497
200806 -1.128 218.815 -1.193
200809 -9.953 218.783 -10.527
200812 -19.942 210.228 -21.951
200903 -27.721 212.709 -30.158
200906 -39.279 215.693 -42.141
200909 -49.907 215.969 -53.474
200912 -60.105 215.949 -64.407
201003 -69.826 217.631 -74.246
201006 -80.198 217.965 -85.144
201009 -92.000 218.439 -97.462
201012 29.361 219.179 30.999
201103 25.398 223.467 26.300
201106 22.042 225.722 22.597
201109 18.476 226.889 18.844
201112 15.271 225.672 15.659
201203 15.283 229.392 15.417
201206 11.458 229.478 11.554
201209 6.928 231.407 6.928

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Helix Biomedix Business Description

Address 19125 North Creek Parkway, Suite 120, Bothell, WA, USA, 98011
Helix Biomedix Inc is a Delaware-based biopharmaceutical company that focuses on the early-stage development of peptide-based therapeutics for dermatology and skin health. The Company is in the preclinical stage, advancing a rare disease drug program for xeroderma pigmentosum, and plans to seek orphan drug designation before entering clinical development. Leveraging its proprietary peptide technology, Helix BioMedix aims to address unmet needs in rare dermatological conditions and has a history of developing patented bioactive peptides for topical personal care use.